Diabetic ketoacidosis is a dangerous complication of diabetes where the body produces too much acid. When this condition leads to a rare lung infection called pulmonary mucormycosis, the outlook is often grim. A recent look at 16 patients shows that one in four people with this specific combination died. This group included one detailed case report and 15 cases gathered from medical literature. The infection was caused by a fungus known as Rhizopus. Doctors treated these patients with amphotericin B-based therapy and performed surgery to remove localized lesions when possible. They also worked to correct the underlying metabolic issues. The review did not report any specific safety signals or side effects for the drugs used in these cases. However, the data comes from a small number of patients and a mix of treatment settings. This means the results reflect real-world complexity rather than a single controlled experiment. The main lesson is clear: doctors must keep a high index of clinical suspicion in high-risk hosts. Early pathological or molecular diagnosis is vital. Prompt antifungal therapy alongside metabolic correction saves lives. Timely surgical evaluation for localized lesions remains a critical part of care. Maintaining these practices could improve outcomes for patients facing this deadly threat.
Review of 16 cases shows 25% mortality for pulmonary mucormycosis in DKA patients treated with amphotericin BTreatment for rare lung infection kills one in four patients with diabetic ketoacidosis
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This publication is a case report and literature review focusing on patients with diabetic ketoacidosis (DKA) complicated by invasive pulmonary mucormycosis caused by Rhizopus. The scope includes 16 patients, comprising one case report and 15 cases drawn from the literature. The setting of care was not reported for this aggregated group. The primary outcome assessed was overall mortality.
The authors report an overall mortality rate of 25%, which corresponds to 4 deaths among the 16 patients included in the analysis. No p-values or confidence intervals were reported for this finding. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the source material.
The intervention involved amphotericin B-based therapy and surgical resection for localized lesions. The authors note that the comparator was not reported. Key practice arguments include maintaining a high index of clinical suspicion in high-risk hosts, ensuring early pathological or molecular diagnosis, initiating prompt antifungal therapy alongside metabolic correction, and seeking timely surgical evaluation for localized lesions. Funding or conflicts of interest were not reported.